Nonalcoholic Fatty Liver Disease in Lean Subjects: Associations With Metabolic Dysregulation and Cardiovascular Risk-A Single-Center Cross-Sectional Study.
Journal
Clinical and translational gastroenterology
ISSN: 2155-384X
Titre abrégé: Clin Transl Gastroenterol
Pays: United States
ID NLM: 101532142
Informations de publication
Date de publication:
05 04 2021
05 04 2021
Historique:
received:
28
09
2020
accepted:
27
01
2021
entrez:
6
4
2021
pubmed:
7
4
2021
medline:
10
9
2021
Statut:
epublish
Résumé
Although a milder metabolic phenotype of nonalcoholic fatty liver disease (NAFLD) in lean patients (body mass index [BMI] <25 kg/m2) compared to overweight/obese patients with NAFLD is assumed, the relevance of NAFLD among lean subjects remains a matter of debate. We aimed to characterize the metabolic/cardiovascular phenotype of lean patients with NAFLD. In total, 3,043 subjects (cohort I) and 1,048 subjects (cohort II) undergoing screening colonoscopy between 2010 and 2020 without chronic liver disease other than NAFLD were assigned to one of the following groups: lean patients without NAFLD, lean NAFLD, overweight NAFLD (BMI 25-30 kg/m2), and obese NAFLD (BMI >30 kg/m2). Diagnosis of NAFLD was established using ultrasound (cohort I) and controlled attenuation parameter (cohort II). The prevalence of lean patients with NAFLD was 6.7%/16.1% in the overall cohort I/II and 19.7%/40.0% in lean subjects of cohort I/II. Compared with lean subjects without NAFLD, lean patients with NAFLD had a higher prevalence of dyslipidemia, dysglycemia, and the metabolic syndrome, together with a higher median Framingham risk score in both cohorts (all P < 0.001). On multivariable analyses, NAFLD in lean subjects was associated with higher odds of metabolic syndrome (adjusted odds ratio cohort I: 4.27 [95% confidence interval (CI): 2.80-6.51], P < 0.001; cohort II: 2.97 [95% CI: 1.40-6.33], P < 0.001), and higher Framingham risk score (regression coefficient B cohort I: 1.93 [95% CI: 0.95-2.92], P < 0.003; cohort II: 1.09 [95% CI: 0.81-2.10], P = 0.034), among others. Only 69.8% of lean patients with NALFD in cohort I and 52.1% in cohort II fulfilled the novel criteria for metabolic associated fatty liver disease. NAFLD in lean patients is associated with the metabolic syndrome and increased cardiovascular risk. Novel metabolic associated fatty liver disease criteria leave a considerable proportion of patients unclassified.
Identifiants
pubmed: 33821832
doi: 10.14309/ctg.0000000000000326
pii: 01720094-202104000-00003
pmc: PMC8345908
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00326Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.
Références
Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol 2015;62:S47–64.
Sasaki A, Nitta H, Otsuka K, et al. Bariatric surgery and non-alcoholic fatty liver disease: Current and potential future treatments. Front Endocrinol (Lausanne) 2014;5:164.
Wu KT, Kuo PL, Su SB, et al. Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. J Clin Lipidol 2016;10:420–5.e1.
Shi Y, Wang Q, Sun Y, et al. The prevalence of lean/nonobese nonalcoholic fatty liver disease: A systematic review and meta-analysis. J Clin Gastroenterol 2020;54:378–87.
Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:739–52.
Stefan N, Schick F, Haring HU. Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. Cell Metab 2017;26:292–300.
Younossi ZM, Stepanova M, Negro F, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 2012;91:319–27.
Fracanzani AL, Petta S, Lombardi R, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity. Clin Gastroenterol Hepatol 2017;15:1604–11.e1.
Young S, Tariq R, Provenza J, et al. Prevalence and profile of nonalcoholic fatty liver disease in lean adults: Systematic review and meta-analysis. Hepatol Commun 2020;4:953–72.
Niederseer D, Bracher I, Stadlmayr A, et al. Association between cardiovascular risk and diabetes with colorectal neoplasia: A site-specific analysis. J Clin Med 2018;7:484.
Stadlmayr A, Aigner E, Steger B, et al. Nonalcoholic fatty liver disease: An independent risk factor for colorectal neoplasia. J Intern Med 2011;270:41–9.
Semmler G, Wöran K, Scheiner B, et al. Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis. United Eur Gastroenterol J 2020;8:321–31.
Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 2017;66:1022–30.
Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–5.
Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37(Suppl 1):S81–90.
Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020;73:202–9.
Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837–47.
Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol 2016;23:NP1–96.
McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010;59:1265–9.
Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep 2019;1:329–41.
Feldman A, Eder SK, Felder TK, et al. Clinical and metabolic characterization of lean Caucasian subjects with non-alcoholic fatty liver. Am J Gastroenterol 2017;112:102–10.
Xu C, Yu C, Ma H, et al. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: The Zhejiang Zhenhai Study. Am J Gastroenterol 2013;108:1299–304.
Feng RN, Du SS, Wang C, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol 2014;20:17932–40.
Sinn DH, Gwak GY, Park HN, et al. Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults. Am J Gastroenterol 2012;107:561–7.
Wei JL, Leung JCF, Loong TCW, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: A population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol 2015;110:1306–14.
Erkan G, Sayın I, Polat FB, et al. The relationship between insulin resistance, metabolic syndrome and nonalcoholic fatty liver disease in non-obese non-diabetic Turkish individuals: A pilot study. Turk J Gastroenterol 2014;25(Suppl 1):63–8.
Petersen KF, Dufour S, Feng J, et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci USA 2006;103:18273–7.
Wulan SN, Westerterp KR, Plasqui G. Ethnic differences in body composition and the associated metabolic profile: A comparative study between Asians and Caucasians. Maturitas 2010;65:315–9.
Rampal S, Mahadeva S, Guallar E, et al. Ethnic differences in the prevalence of metabolic syndrome: Results from a multi-ethnic population-based survey in Malaysia. PLoS One 2012;7:e46365.
Weinberg EM, Trinh HN, Firpi RJ, et al. Lean Americans with nonalcoholic fatty liver disease have lower rates of cirrhosis and co-morbid diseases. Clin Gastroenterol Hepatol 2020;S1542-3565(20)30930-7.
Lindsay RS, Wake DJ, Nair S, et al. Subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab 2003;88:2738–44.
Tabák AG, Herder C, Rathmann W, et al. Prediabetes: A high-risk state for diabetes development. Lancet 2012;379:2279–90.
Kitade H, Chen G, Ni Y, et al. Nonalcoholic fatty liver disease and insulin resistance: New insights and potential new treatments. Nutrients 2017;9:387.
Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:330–44.
Adams LA, Anstee QM, Tilg H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017;66:1138–53.
Niederseer D, Wernly S, Bachmayer S, et al. Diagnosis of non-alcoholic fatty liver disease (NAFLD) is independently associated with cardiovascular risk in a large Austrian screening cohort. J Clin Med 2020;9:1065.
Golabi P, Paik J, Fukui N, et al. Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality. Clin Diabetes 2019;37:65–72.
Younes R, Rosso C, Petta S, et al. Usefulness of the index of NASH-ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. Liver Int 2018;38:715–23.
Karmali KN, Persell SD, Perel P, et al. Risk scoring for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2017;3:CD006887.
Golabi P, Paik J, Reddy R, et al. Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States. BMC Gastroenterol 2019;19:56.
Dasarathy S, Dasarathy J, Khiyami A, et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: A prospective study. J Hepatol 2009;51:1061–7.
Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology 2011;54:1082–90.
Teeratorn N, Piyachaturawat P, Thanapirom K, et al. Screening for non-alcoholic fatty liver disease in community setting: A cohort study using controlled attenuation parameter-transient elastography. JGH Open 2020;4:245–50.
Younossi ZM, Rinella ME, Sanyal A, et al. From NAFLD to MAFLD: Implications of a premature change in terminology. Hepatology 2021;73:1194–8.
Lin S, Huang J, Wang M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 2020;40:2082–9.
Targher G. Concordance of MAFLD and NAFLD diagnostic criteria in “real-world” data. Liver Int 2020;40:2879–80.
Huang J, Kumar R, Wang M, et al. MAFLD criteria overlooks a number of patients with severe steatosis: Is it clinically relevant? J Hepatol 2020;73:1265–7.
Targher G, Byrne CD. From nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease: Is it time for a change of terminology? Hepatoma Res 2020;6:64.
Younes R, Bugianesi E. NASH in lean individuals. Semin Liver Dis 2019;39:86–95.
Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461–5.